Trial Summary
What is the purpose of this trial?
This trial investigates whether a one-month course of preventative (prophylactic) antibiotics helps to reduce urinary tract infections after robot-assisted surgery to remove all of the bladder as well as nearby tissues and organs (radical cystectomy). Urinary tract infections are a common occurrence after robot-assisted radical cystectomy. Antibiotics such as trimethoprim-sulfamethoxazole or nitrofurantoin may prevent or control infections in patients with urinary tract infection and may help improve their response to radical cystectomy. Information gained from this study may help researchers to predict patient complications and identify better ways to manage these complications.
Research Team
Khurshid A. Guru
Principal Investigator
Roswell Park Cancer Institute
Eligibility Criteria
This trial is for patients planning to undergo robot-assisted surgery to remove the bladder due to muscle-invasive or refractory non-muscle invasive bladder cancer. Participants must understand and consent to the study's nature. Excluded are those with myasthenia gravis, QT prolongation, severe kidney issues, pregnant/nursing women, and anyone who can't follow the protocol.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Clindamycin (Antibiotic)
- Diary (Other)
- Ertapenem (Antibiotic)
- Levofloxacin (Antibiotic)
- Nitrofurantoin (Antibiotic)
- Trimethoprim-Sulfamethoxazole (Antibiotic)
Clindamycin is already approved in Canada, Japan for the following indications:
- Serious bacterial infections
- Anaerobic bacterial infections
- Streptococcal infections
- Staphylococcal infections
- Pneumococcal infections
- Serious bacterial infections
- Anaerobic bacterial infections
- Streptococcal infections
- Staphylococcal infections
- Pneumococcal infections
Find a Clinic Near You
Who Is Running the Clinical Trial?
Roswell Park Cancer Institute
Lead Sponsor
Dr. Julia Faller
Roswell Park Cancer Institute
Chief Medical Officer since 2024
DO from an unspecified institution
Dr. Candace S. Johnson
Roswell Park Cancer Institute
Chief Executive Officer since 2015
PhD in Immunology from The Ohio State University